[DEPO] Depomed, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 1.16 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.49 Change: 0.5 (2.78%)
Ext. hours: Change: 0 (0%)

chart DEPO

Refresh chart

Strongest Trends Summary For DEPO

DEPO is in the long-term up 107% in 17 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other conditions, and diseases of the central nervous system in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Lazanda (fentanyl) Nasal Spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is also involved in the clinical development of DM-1992 that completed a Phase II trial for Parkinson's disease. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. It has license and collaboration agreements with Abbott Products Inc.; Santarus, Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceu

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding61.1 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -52.46% Sales Growth - Q/Q-83.45% P/E
P/E To EPS Growth P/S3.34 P/BV3.21 Price/Cash Per Share2.06
Price/Free Cash Flow-20.45 ROA14.51% ROE28.38% ROI
Current Ratio9.94 Quick Ratio9.84 Long Term Debt/Equity Debt Ratio0.17
Gross Margin95.79% Operating Margin55.26% Net Profit Margin29.53% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.41 M Cash From Investing Activities-437.81 M Cash From Operating Activities-2.49 M Gross Profit71.64 M
Net Profit-21.65 M Operating Profit-17.21 M Total Assets1.32 B Total Current Assets234.57 M
Total Current Liabilities133.18 M Total Debt813.55 M Total Liabilities976.66 M Total Revenue94.5 M
Technical Data
High 52 week10.91 Low 52 week4.56 Last close8.74 Last change-1.35%
RSI66.44 Average true range0.3 Beta1.07 Volume711.14 K
Simple moving average 20 days6.51% Simple moving average 50 days18.76% Simple moving average 200 days24.16%
Performance Data
Performance Week4.67% Performance Month28.15% Performance Quart39.17% Performance Half18.91%
Performance Year-13.47% Performance Year-to-date8.57% Volatility daily4.04% Volatility weekly9.03%
Volatility monthly18.5% Volatility yearly64.1% Relative Volume198.99% Average Volume1.43 M
New High New Low

News

2018-11-04 21:24:10 | Hedge Fund Governors Lane Is Betting On A Seth Klarman Favorite

2018-08-15 06:00:00 | Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc.

2018-08-11 08:02:44 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-08-08 09:11:25 | Depomed: 2Q Earnings Snapshot

2018-08-08 08:02:58 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-08-08 07:30:00 | Depomed Announces Second-Quarter 2018 Financial Results

2018-08-08 06:30:00 | Depomed, Inc. to Host Earnings Call

2018-08-02 08:02:19 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-07-31 08:02:16 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-07-31 07:45:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly — New Research Emphasizes Economic Growth

2018-07-30 08:25:00 | Report: Developing Opportunities within Facebook, Depomed, Freeport-McMoRan, The Home Depot, Earthstone Energy, and Nuance Communications — Future Expectations, Projections Moving into 2018

2018-07-14 08:03:18 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-07-10 08:20:00 | Today's Research Reports on Trending Tickers: OPKO Health and Depomed

2018-07-09 18:50:00 | [$$] Depomed, Purdue Pharma Move to Resolve Patent Dispute

2018-07-09 08:30:00 | Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

2018-07-09 07:25:00 | Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

2018-07-06 16:05:00 | Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-06-08 08:06:06 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-06-07 17:00:00 | Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-06-07 07:50:00 | Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

2018-06-05 08:30:00 | Depomed Announces the Appointment of Phillip B. Donenberg as Chief Financial Officer

2018-05-22 18:59:22 | Depomed Inc NASDAQ:DEPO Is Trading At A 26% Discount

2018-05-10 21:56:34 | Edited Transcript of DEPO earnings conference call or presentation 10-May-18 12:30pm GMT

2018-05-10 17:40:00 | Why Depomed Inc.'s Shares Soared 23.2% Higher

2018-05-10 09:31:39 | Depomed: 1Q Earnings Snapshot

2018-05-10 08:00:00 | Depomed Announces First-Quarter 2018 Financial Results

2018-05-07 08:00:00 | Depomed to Present at the UBS Global Healthcare Conference

2018-05-03 08:00:00 | Depomed to Report First-Quarter 2018 Financial Results on Thursday, May 10, 2018

2018-04-17 16:05:00 | Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications

2018-04-16 08:10:00 | Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals, Cloudera, and Valero Energy Market Influences — Renewed Outlook, Key Drivers of Growth

2018-04-13 08:07:56 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-04-12 09:51:26 | Does Depomed Inc’s NASDAQ:DEPO Past Performance Indicate A Weaker Future?

2018-04-09 08:07:47 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-04-09 08:00:00 | Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635c4  

2018-04-03 13:19:22 | When Will Depomed Inc NASDAQ:DEPO Become Profitable?

2018-04-02 16:05:00 | Depomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific Officer

2018-03-19 15:23:00 | Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

2018-03-19 15:23:00 | Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

2018-03-19 08:00:00 | Depomed Announces New Corporate Headquarters

2018-03-15 18:30:36 | Should You Follow This Trend For Depomed Inc NASDAQ:DEPO?

2018-03-15 08:07:52 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-03-12 08:08:02 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-03-09 08:20:00 | Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix — New Horizons, Emerging Trends, and Upcoming Developments

2018-03-09 08:07:50 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-03-08 16:48:00 | This Biotech Flirts With Breakout Amid Battle With Opioid Makers

2018-03-08 08:06:51 | See what the IHS Markit Score report has to say about Depomed Inc.

2018-03-08 07:32:46 | Exploring Depomed’s Financial Performance Today

2018-03-07 13:30:30 | Inside Depomed’s Portfolio: The Key Drugs

2018-03-07 13:30:30 | Depomed versus Peers in March 2018: Analyst Ratings

2018-03-07 13:30:30 | Behind Depomed’s Business Strategy